Key Takeaways:
- Abbott announced its intention to separate its nutrition business into an independent, publicly traded company with approximately $8.5 billion in annual sales, including popular brands like Pedialyte, Similac, and Ensure.
- In Abbott’s third quarter, the nutrition business generated revenue of $2.26 billion, marking a 5% year-over-year growth.
- Recent lawsuits and a federal investigation into Abbott’s nutrition business stem from a 2022 recall of powdered infant formula due to potential contamination, leading to a $385 million settlement with the Department of Justice.
Insightful Analysis:
Following in the footsteps of other medtech companies, Abbott’s decision to spin out its nutrition business is seen as a strategic move to optimize growth opportunities and focus on higher-growth markets.
CEO Robert Ford believes that this separation will allow the nutrition business to capitalize on the demand for healthy nutrition independently, while enabling the remaining company to concentrate on medical devices, diagnostics, and established medicines.
Post-spin, Abbott’s core businesses will include diagnostics, established pharmaceuticals, and medical devices, with an estimated $42 billion in sales.
The spin-off is expected to be finalized by the end of 2027, pending regulatory approval, with Abbott stockholders owning shares in both entities.
The planned separation is unlikely to impact Abbott’s guidance for 2026 or 2027, with further details to be provided in January.
Industry analysts view the spinout positively, anticipating improved growth and margins for Abbott as it navigates away from challenges in the nutrition market.
Despite ongoing litigation related to the nutrition business, Abbott remains focused on completing the separation, with litigation resolution not being a prerequisite for the spinout.
Abbott’s third-quarter earnings of $13.01 billion reflected a 14.5% growth, although the company revised its 2026 sales growth guidance to 6%.